Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $11.50 Average Target Price from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $12.80.

Several research analysts have recently weighed in on INO shares. Oppenheimer lowered their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, November 18th. HC Wainwright lowered their target price on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Monday, November 18th. Royal Bank of Canada cut their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Friday, November 15th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a research note on Friday.

Inovio Pharmaceuticals Stock Down 5.3 %

Shares of NASDAQ INO opened at $1.98 on Friday. The company has a market capitalization of $51.68 million, a PE ratio of -0.95 and a beta of 0.84. Inovio Pharmaceuticals has a twelve month low of $1.74 and a twelve month high of $14.75. The firm has a fifty day simple moving average of $3.42 and a 200 day simple moving average of $6.10.

Institutional Trading of Inovio Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Barclays PLC boosted its stake in Inovio Pharmaceuticals by 282.6% during the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 25,116 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Inovio Pharmaceuticals in the third quarter valued at approximately $379,000. State Street Corp boosted its position in shares of Inovio Pharmaceuticals by 11.7% during the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock valued at $2,836,000 after buying an additional 51,414 shares during the last quarter. Finally, Atom Investors LP bought a new stake in Inovio Pharmaceuticals during the third quarter worth $103,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.